Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
Go back to Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 286.41 +8.32 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $278.09 | 52 Week High | $109.10 | |||
| Open | $278.42 | 52 Week Low | $31.38 | |||
| Day High | $286.67 | P/E | N/A | |||
| Day Low | $278.17 | EPS | $-1.45 | |||
| Volume | 1,420,698 | |||||
